Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate vs Luteal Phase Oophorectomy and Tamoxifen in Premenopausal Breast Cancer
NCT00201851Phase 3Completed
- Sponsor
- International Breast Cancer Research Foundation
- Start
- Jan 2004
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of tamoxifen in breast cancer (3 arms), sponsored by International Breast Cancer Research Foundation. Primary endpoint: Disease-free Survival at 3 years. Started Jan 2004; status: completed.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00201851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00201851.